Somai Pharmaceuticals Partners with Airo Brands for Global Expansion

Business by 2FIRSTS.ai

Feb.07.2024

Somai Pharmaceuticals Partners with Airo Brands for Global Expansion

Portuguese pharmaceutical company Somai Pharmaceuticals announced its entry into the Australian market in collaboration with Airo Brands.

Portuguese-based pharmaceutical company Somai Pharmaceuticals recently announced its entry into the Australian market. The company plans to collaborate with American e-cigarette company Airo Brands to manufacture and distribute a range of e-cigarette and e-liquid products.

Pharmaceutical company Somei operates a 3800-square-meter factory near Lisbon, where it exclusively produces the Airo e-cigarette battery technology and its AiroPod e-liquid formula. The first batch of products is expected to be launched in the second quarter of this year under the Special Access Scheme, and sales are also anticipated in Germany, Poland, and Switzerland.

Airo Company was established in 2017 and its innovative tobacco products have been licensed for sale in more than 1700 medical and adult-use marijuana dispensaries across 23 states in the United States and Puerto Rico.

For Solmax, a company engaged in the extraction, research, development, formulation, and distribution of pharmaceutical cannabis products complying with EU GMP regulations, the Airo product holds the potential to become their first batch of products distributed in Australia.

Somai Founder and CEO, Michael Sassano, expressed that this collaboration will position Airo "ahead of other companies in global expansion." He stated, "Our Airo products will meet the European Union GMP quality standards worldwide, and as the global market expands, we will propel the entire Airo product range into an even brighter future." Both Europe and other continents are progressing, and we are honored to bring the finest vaporizers to the global market.

Richard Yost, CEO of Airo, has referred to this collaboration as a "milestone" and emphasized the significance of finding a partner that shares their commitment to quality and consumer focus. According to Yost, they have identified these qualities in Soma.

We were not only impressed by their advanced factory in Portugal, but also by the quality of their team.

Also Read:

[1] Portuguese Parliament Approves EU Tobacco Directive in Urgent Decision

[2] Illegal E-cig Market in Victoria, Australia Predicted to be AUD 500M

[3] New South Wales Government Requires Sellers to Report Tobacco and E-Cigarettes

#Brands

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved

Altria’s new nicotine pouch On! PLUS™ is slated to launch in the U.S. on October 14, debuting in North Carolina, Texas, and Florida. The product uses NICOSILK™ technology and will offer multiple nicotine strengths. FDA approval has not yet been granted, but Helix says it is proceeding in line with compliance requirements.

Oct.11 by 2FIRSTS.ai

South Korea National Assembly Approves Bill to Regulate E-Cigarettes Under Tobacco Law After Nine Years of Debate

South Korea’s National Assembly Legislation and Judiciary Committee passed a long-debated amendment to the Tobacco Business Act on November 26, expanding the legal definition of tobacco to include synthetic nicotine e-cigarettes. The amendment aims to end the regulatory blind spot surrounding such products while ensuring transitional support for vape retailers and a grace period for compliance.

Nov.26 by 2FIRSTS.ai

PMI Japan Unveils Limited-Edition IQOS ILUMA i “Galaxy Blue,” Priced Around $47

Philip Morris Japan announced it will release the limited-edition IQOS ILUMA i “Galaxy Blue” across IQOS stores nationwide starting October 29, priced at JPY 6,980 including tax (about USD 47). The new model features a space-themed design, with a members-only promotion to run at the Nagoya IQOS store.

Oct.29 by 2FIRSTS.ai

CSUR, the Research Institute Supporting Juul’s PMTA Research, Outlines a New Pathway for Nicotine Pouches

CSUR—the Research Institute Supporting Juul and NJOY’s successful PMTAs—assessed FDA’s pilot for nicotine pouches. The program expedites premarket review by deferring behavioral data to post-market reporting. CSUR says this could speed authorizations, but manufacturers must still produce behavioral and real-world evidence after a Marketing Granted Order to maintain compliance with public-health standards.